Electron beam radiotherapy for the management of squamous cell carcinoma of the anal margin

Abstract

Purpose and objective: Squamous cell carcinoma of the anal margin (SCCAM) is an uncommon lesion that comprises one-third to a quarter of all anal squamous cell carcinoma. Treatment involves surgery or exclusive radiotherapy for small tumours, whereas the preferred treatment for larger tumours is chemoradiotherapy. In our department, selected patients with SCCAM are treated with electron beam radiotherapy using one perineal field. The present study evaluates this strategy. Material and methods: All consecutive patients with SCCAM and treated with electron beam radiotherapy from 2012 to 2022 were included. Data were retrospectively extracted from the medical records and analysed descriptively. Local control (LC) and overall survival (OS) were analysed using Kaplan-Meier statistics. Results: Forty patients were evaluated. Primary radiotherapy was delivered in 35 (87.5%) patients. Five (12.5%) patients had postoperative radiotherapy. Median prescription dose was 60.0 (range 45.0–60.2) Gy in 28 (range 10–30) fractions delivered with 8 (range 4–18) MeV using a standard circular aperture and bolus. At a median follow-up of 73 (range 9–135) months, 7 (17.5%) patients were diagnosed with local recurrences. The 5-year LC rate was 84.3% (95% CI: 71.4%–97.2%). Analysis of LC according to T-stage revealed a 5-year LC of 100% (95% CI: 100%–100%) in T1 tumours compared to 57.0% (95% CI: 27.4%–86.6%) in T2 tumours (p < 0.001). 5-year OS was 91.6% (95% CI: 83.0%–100%). Late grade 3 toxicity included ulceration in the skin and subcutis in 2 (5.0%) patients. Intepretation: Electron beam radiotherapy enables the delivery of ‘eye-guided’ radiotherapy directly to the tumour. LC is good in patients with T1 tumours. Patients with T2 tumours have less satisfactory LC and should be treated with chemoradiotherapy. Electron beam radiotherapy enables the delivery of “eye-guided” RT directly to the tumour. LC is excellent in patients with T1 tumours. Patients with T2 tumours have less satisfactory LC and should be treated with chemoradiotherapy.